NCT06798896Phase 2Recruiting

RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

Study sponsor: Supernus Pharmaceuticals, Inc. · SUPN

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-08Estimated
Enrollment · participants216Estimated
Source updated2026-10-01Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Planned enrollment decreased by 42 participants

Before: 258 participants (planned). After: 216 participants (planned).

Primary completion date changed

Before: Oct 2026. After: Aug 2027.

Check registry source